1. Huang FC, Huang SP, Tseng SH. Management of infectious scleritis after pterygium excision. Cornea. 2000. 19:34–39.
2. Fincher T, Fulcher SF. Diagnostic and therapeutic challenge of aspergillus flavus scleritis. Cornea. 2007. 26:618–620.
3. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008. 111:3388–3394.
4. Garcia Marrero RD, Alonso Socas MM, Oramas Rodriguez J, et al. Several episodes of bacterial infections in a patient with monoclonal gammapathy of undetermined significance. An Med Interna. 2006. 23:452.
5. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, et al. Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases. Pathol Biol. 2005. 53:19–25.
6. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma call discorders: diagnosis and treatment. Mayo Clin Proc. 2006. 81:693–703.
7. Rodriguez-Ares MT, De Rojas Silva MV, Pereiro M, et al. Aspergillus fumigatus scleritis. Acta Ophthalmol Scand. 1995. 73:467–469.
8. Stewart RM, Quah SA, Neal TJ, Kaye SB. The use of voriconazole in the treatment of Aspergillus fumigatus keratitis. Br J Ophthalmol. 2007. 91:1094–1096.
9. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004. 137:820–825.
10. Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother. 2007. 51:239–244.
11. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002. 346:564–569.